TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to assess the safety and effectiveness of two concentrations of IDP-108 in treating patients with onychomycosis


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Low Strength IDP-108 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: High Strength IDP-108 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: High Strength IDP-108 under occlusion | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: Low Strength IDP-108; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: High Strength IDP-108; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: High Strength IDP-108 under occlusion; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): 4
B: Arm Label: IDP-108; Type: EXPERIMENTAL; Interventions: Drug: IDP-108 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: IDP-108; Assigned to Arm(s): IDP-108 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
C: Arm Label: IDP-108; Type: EXPERIMENTAL; Interventions: Drug: IDP-108 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: IDP-108; Assigned to Arm(s): IDP-108 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: Excilor Forte; Type: EXPERIMENTAL; Interventions: Device: Excilor Forte | Arm Label: Loceryl 5%; Type: ACTIVE_COMPARATOR; Interventions: Drug: Loceryl 5% | Intervention Type: DEVICE; Name: Excilor Forte; Assigned to Arm(s): Excilor Forte | Intervention Type: DRUG; Name: Loceryl 5%; Assigned to Arm(s): Loceryl 5%

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Heart Disease in Underserved Patients
Brief Summary: The study will evaluate the impact of an internet based telemedicine system on cardiovascular risk profile of underserved patient populations. It is our hypothesis that a treatment plan and frequent communication via an internet based Telemedicine system will improve the cardiovascular risk profile of underserved patient populations at increased risk for cardiovascular disease. Our primary endpoint is a reduction over one year in the 10-year CVD risk score (ATP III risk model).


Options:
A: Arm Label: Smart phone app glucose monitoring; Type: EXPERIMENTAL; Interventions: Device: Blue tooth enabled glucose meter with smart phone application, Behavioral: Self home blood glucose monitoring | Arm Label: Standard glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self home blood glucose monitoring | Intervention Type: DEVICE; Name: Blue tooth enabled glucose meter with smart phone application; Assigned to Arm(s): Smart phone app glucose monitoring | Intervention Type: BEHAVIORAL; Name: Self home blood glucose monitoring; Assigned to Arm(s): Smart phone app glucose monitoring, Standard glucose monitoring
B: Arm Label: Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Telemonitoring | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: DEVICE; Name: Telemonitoring; Assigned to Arm(s): Telemonitoring | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control group
C: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring
D: Arm Label: telemedicine; Type: EXPERIMENTAL; Interventions: Behavioral: telemedicine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telemedicine; Assigned to Arm(s): telemedicine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Heart Disease in Underserved Patients
Brief Summary: The study will evaluate the impact of an internet based telemedicine system on cardiovascular risk profile of underserved patient populations. It is our hypothesis that a treatment plan and frequent communication via an internet based Telemedicine system will improve the cardiovascular risk profile of underserved patient populations at increased risk for cardiovascular disease. Our primary endpoint is a reduction over one year in the 10-year CVD risk score (ATP III risk model).


Options:
A: Arm Label: telemedicine; Type: EXPERIMENTAL; Interventions: Behavioral: telemedicine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telemedicine; Assigned to Arm(s): telemedicine
B: Arm Label: Technology-supported care; Type: EXPERIMENTAL; Interventions: Other: Technology-supported care | Arm Label: Supported-Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Technology-supported care; Assigned to Arm(s): Technology-supported care
C: Arm Label: Breastfeeding promotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion intervention; Assigned to Arm(s): Breastfeeding promotion intervention
D: Arm Label: Electronic monitor + no text message; Type: PLACEBO_COMPARATOR; Interventions: Device: Electronic + no text message | Arm Label: Electronic monitor + Text message; Type: EXPERIMENTAL; Interventions: Device: Electronic monitor + text messages | Intervention Type: DEVICE; Name: Electronic + no text message; Assigned to Arm(s): Electronic monitor + no text message | Intervention Type: DEVICE; Name: Electronic monitor + text messages; Assigned to Arm(s): Electronic monitor + Text message

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Heart Disease in Underserved Patients
Brief Summary: The study will evaluate the impact of an internet based telemedicine system on cardiovascular risk profile of underserved patient populations. It is our hypothesis that a treatment plan and frequent communication via an internet based Telemedicine system will improve the cardiovascular risk profile of underserved patient populations at increased risk for cardiovascular disease. Our primary endpoint is a reduction over one year in the 10-year CVD risk score (ATP III risk model).


Options:
A: Arm Label: Arm 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Behavioral intervention with Home BP Telemonitoring | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Medication Management with Home BP Telemonitoring | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Combined intervention with Home BP Telemonitoring | Intervention Type: BEHAVIORAL; Name: Nurse Behavioral intervention with Home BP Telemonitoring; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Nurse Medication Management with Home BP Telemonitoring; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: Nurse Combined intervention with Home BP Telemonitoring; Assigned to Arm(s): Arm 4
B: Arm Label: U-healthcare; Type: EXPERIMENTAL; Interventions: Device: U-healthcare service | Arm Label: SMBG group; Type: ACTIVE_COMPARATOR; Interventions: Device: SMBG group | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: U-healthcare service; Assigned to Arm(s): U-healthcare | Intervention Type: DEVICE; Name: SMBG group; Assigned to Arm(s): SMBG group
C: Arm Label: telemedicine; Type: EXPERIMENTAL; Interventions: Behavioral: telemedicine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telemedicine; Assigned to Arm(s): telemedicine
D: Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Arm Label: Informational SMS-text; Type: EXPERIMENTAL; Interventions: Behavioral: Informational SMS-text, Behavioral: Enhanced usual care | Arm Label: Interactive SMS-text; Type: EXPERIMENTAL; Interventions: Behavioral: Informational SMS-text, Behavioral: Interactive SMS-text, Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Informational SMS-text; Assigned to Arm(s): Informational SMS-text, Interactive SMS-text | Intervention Type: BEHAVIORAL; Name: Interactive SMS-text; Assigned to Arm(s): Interactive SMS-text | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care, Informational SMS-text, Interactive SMS-text

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Remote Patient Monitoring on Heart Failure Management: A Randomized Controlled Trial
Brief Summary: The purpose of this randomized controlled trial is to determine the effects of a user-centric remote patient monitoring system on heart failure management. Patients attending a Heart Failure Clinic will monitor their weight, blood pressure, ECG, and symptoms at home. The hypothesis is that the remote monitoring system will improve heart failure outcomes through increased self-care and improved clinical management.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Arm Label: 2; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
B: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
C: Arm Label: TREATMENT Group; Type: ACTIVE_COMPARATOR; Interventions: Device: HF Pressure Measurement System | Arm Label: CONTROL Group; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DEVICE; Name: HF Pressure Measurement System; Assigned to Arm(s): TREATMENT Group
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention - a validated home BP monitor and support from the specialist nurse | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control - usual care (BP monitoring by their practice) | Intervention Type: BEHAVIORAL; Name: Intervention - a validated home BP monitor and support from the specialist nurse; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Control - usual care (BP monitoring by their practice); Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Remote Patient Monitoring on Heart Failure Management: A Randomized Controlled Trial
Brief Summary: The purpose of this randomized controlled trial is to determine the effects of a user-centric remote patient monitoring system on heart failure management. Patients attending a Heart Failure Clinic will monitor their weight, blood pressure, ECG, and symptoms at home. The hypothesis is that the remote monitoring system will improve heart failure outcomes through increased self-care and improved clinical management.


Options:
A: Arm Label: Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice, Behavioral: Poor weather forecast warning | Arm Label: No Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD self care advice; Assigned to Arm(s): Forecast, No Forecast | Intervention Type: BEHAVIORAL; Name: Poor weather forecast warning; Assigned to Arm(s): Forecast
B: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
C: Intervention Type: BEHAVIORAL; Name: Targeted parental instruction for positive lifestyle change with follow-up calls.; Assigned to Arm(s): N/A
D: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Remote Patient Monitoring on Heart Failure Management: A Randomized Controlled Trial
Brief Summary: The purpose of this randomized controlled trial is to determine the effects of a user-centric remote patient monitoring system on heart failure management. Patients attending a Heart Failure Clinic will monitor their weight, blood pressure, ECG, and symptoms at home. The hypothesis is that the remote monitoring system will improve heart failure outcomes through increased self-care and improved clinical management.


Options:
A: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
B: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
C: Arm Label: text message medication reminders; Type: EXPERIMENTAL; Interventions: Behavioral: text message medication reminders | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text message medication reminders; Assigned to Arm(s): text message medication reminders
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prevention Consult; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prevention Consult | Arm Label: Consult & Behavioral Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Consult & Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Prevention Consult; Assigned to Arm(s): Prevention Consult | Intervention Type: BEHAVIORAL; Name: Consult & Behavioral Intervention; Assigned to Arm(s): Consult & Behavioral Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers
Brief Summary: The central hypothesis to be tested in this study is that dual blockade of EGFR and Src pathways or proteins are distinct compared to inhibition of either kinase alone in head and neck and lung cancers.


Options:
A: Arm Label: postop chemoradio with cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Radiation: chemoradiotherapy with cisplatin | Arm Label: postop chemoradio (cisplatin)+gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Iressa (Gefitinib) | Intervention Type: DRUG; Name: Iressa (Gefitinib); Assigned to Arm(s): postop chemoradio (cisplatin)+gefitinib | Intervention Type: RADIATION; Name: chemoradiotherapy with cisplatin; Assigned to Arm(s): postop chemoradio with cisplatin
B: Arm Label: Afatinib (BIBW 2992); Type: EXPERIMENTAL; Interventions: Drug: Afatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Afatinib; Assigned to Arm(s): Afatinib (BIBW 2992)
C: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Dasatinib + Placebo | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib plus Dasatinib | Arm Label: Arm D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Dasatinib + Placebo; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Erlotinib plus Dasatinib; Assigned to Arm(s): Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm D | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of PCOS (Polycystic Ovary Syndrome)in Morbidly Obese Women - A Randomized Controlled Prospective Dietary Intervention Study
Brief Summary: This study has two phases:

1. In phase 1 of the study (8 weeks),the effect of two different low calorie diets on manifestations of PCOS, including risk factors for the metabolic syndrome and cardiovascular risk profile will be compared.
2. In phase 2 the long term effect (next 44 weeks) on sustained weight-loss and the above mentioned parameters will be compared and evaluated.


Options:
A: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices
B: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement
C: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
D: Arm Label: Fructose 9%; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Compliance | Arm Label: Glucose 9%; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Compliance | Arm Label: High fructose corn syrup 18%; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Compliance | Arm Label: Sucrose 18%; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Compliance | Intervention Type: BEHAVIORAL; Name: Dietary Compliance; Assigned to Arm(s): Fructose 9%, Glucose 9%, High fructose corn syrup 18%, Sucrose 18%

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of PCOS (Polycystic Ovary Syndrome)in Morbidly Obese Women - A Randomized Controlled Prospective Dietary Intervention Study
Brief Summary: This study has two phases:

1. In phase 1 of the study (8 weeks),the effect of two different low calorie diets on manifestations of PCOS, including risk factors for the metabolic syndrome and cardiovascular risk profile will be compared.
2. In phase 2 the long term effect (next 44 weeks) on sustained weight-loss and the above mentioned parameters will be compared and evaluated.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Intervention Type: DRUG; Name: Clomiphene citrate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): B
B: Arm Label: Berberine; Type: EXPERIMENTAL; Interventions: Drug: Berberine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: HCG | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: HCG | Intervention Type: DRUG; Name: HCG; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4

Answer: C